|
| Press Releases |
|
 |
|
| Sunday, September 28, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication |
| China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by CMS on 22 April 2025 for details) together with its subsidiaries, obtained positive results from the phase 3 clinical trial (the "Trial") of ruxolitinib cream (the "Product") in patients with mild to moderate atopic dermatitis (AD) in China. more info >> |
|
|
康哲藥業（867.HK；8A8.SG）創新藥磷酸蘆可替尼乳膏AD中國三期臨床取得積極結果 |
| 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業日期為2025年4月22日發佈的公告）連同其附屬公司取得磷酸蘆可替尼乳膏（「蘆可替尼乳膏」或「產品」）輕中度特應性皮炎（AD）的中國三期藥物臨床研究（「試驗」）積極結果。 more info >> |
|
|
康哲药业（867.HK；8A8.SG）创新药磷酸芦可替尼乳膏AD中国三期临床取得积极结果 |
| 康哲药业控股有限公司（"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）连同其附属公司取得磷酸芦可替尼乳膏（"芦可替尼乳膏"或"产品"）轻中度特应性皮炎（AD）的中国三期药物临床研究（"试验"）积极结果。 more info >> |
|
| Tuesday, September 23, 2025 |
|
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively. more info >> |
|
|
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the "Agreements") with Chongqing Genrix Biopharmaceutical Co., Ltd. ("Genrix Bio") for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, "Vecantoxatug") indicated for passive immunization against tetanus and Silevimig Injection (GR1801, "Silevimig") indicated for passive immunization following suspected rabies virus exposure, respectively. more info >> |
|
|
康哲藥業就用於破傷風被動免疫和狂犬病被動免疫的兩款創新生物製劑達成合作 |
| 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，於2025年9月22日，通過其附屬公司與重慶智翔金泰生物製藥股份有限公司（「智翔金泰」）就兩款1類治療用生物製品分別簽訂獨家合作協議（「協議」），分別為用於破傷風的被動免疫適應症的唯康度塔單抗（GR2001）注射液（「唯康度塔單抗注射液」）以及用於疑似狂犬病病毒暴露後的被動免疫適應症的斯樂韋米單抗（GR1801）注射液（「斯樂韋米單抗注射液」）。 more info >> |
|
|
康哲药业就用于破伤风被动免疫和狂犬病被动免疫的两款创新生物制剂达成合作 |
| 康哲药业控股有限公司（"康哲药业"）欣然宣布，于2025年9月22日，通过其附属公司与重庆智翔金泰生物制药股份有限公司（"智翔金泰"）就两款1类治疗用生物制品分别签订独家合作协议（"协议"），分别为用于破伤风的被动免疫适应症的唯康度塔单抗（GR2001）注射液（"唯康度塔单抗注射液"）以及用于疑似狂犬病病毒暴露后的被动免疫适应症的斯乐韦米单抗（GR1801）注射液（"斯乐韦米单抗注射液"）。 more info >> |
|
| Tuesday, August 19, 2025 |
|
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers |
| more info >> |
|
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers |
| On 18 August, China Medical System Holdings Limited ("CMS" or the "Company") announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. more info >> |
|
|
康哲药业（867.HK，8A8.SG）上半年营收净利双升 战略转型跑出增长新动能 |
| 康哲药业发布2025年中期业绩，公司营收和利润同比均实现增长，战略转型成效初显。报告期内，公司实现营业收入约40.0亿元（人民币，下同），同比增长10.8%。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱造船と日本製鉄が低圧液化CO₂タンクの新規鋼材と熱処理（PWHT）省略技術を開発
Dec 5, 2025 11:30: JST
|
|
|
LEXUS、バッテリーEVスポーツカーのコンセプトモデル「Lexus LFA Concept」を世界初公開
Dec 5, 2025 11:20: JST
|
|
|
Doubleview Extends High-Grade Domains at Hat: H099 Returns 438m of 0.40% CuEq Including 52m of 1.02% CuEq, Expanding Mineralization Envelope Around Conceptual Pit Vertically and Laterally
Dec 4, 2025 21:59 HKT/SGT
|
|
|
Business of IP Asia (BIP Asia) Forum and Entrepreneur Day open today
Dec 4, 2025 21:00 HKT/SGT
|
|
|
CaoCao Unveils '100 Cities, 100 Billion in 10 Years' Robotaxi Strategy, Officially Launches World's First 'Green Intelligent Mobility Hub'
Dec 4, 2025 21:00 HKT/SGT
|
|
|
曹操出行發佈Robotaxi「十年百城千億」戰略目標 全球首個「綠色智慧通行島」正式啟用
Dec 4, 2025 18:18 HKT/SGT
|
|
|
The Gourmet's Guide: Using Your TravelKon eSIM to Hunt for Japan's Best Ramen, Sushi, and Street Food
Dec 4, 2025 17:45 HKT/SGT
|
|
|
Spritzer Celebrates Global and Regional Brand Excellence 2025
Dec 4, 2025 12:45 HKT/SGT
|
|
|
Honda、新型「CR-V」の先行予約開始
Dec 4, 2025 11:30: JST
|
|
|
在聯泓格潤「超級工廠」看見綠色材料全鏈路
Dec 4, 2025 09:36 HKT/SGT
|
|
|
在联泓格润"超级工厂" 看见绿色材料全链路
Dec 4, 2025 09:14 HKT/SGT
|
|
|
阿曼十年黃金居留計劃吸引全球投資者尋求穩定與長期通達
Dec 4, 2025 08:00 HKT/SGT
|
|
|
阿曼十年黄金居留计划吸引全球投资者寻求稳定与长期准入
Dec 4, 2025 08:00 HKT/SGT
|
|
|
Oman's 10-Year Golden Residency Program Attracts Global Investors Seeking Stability and Long-Term Access
Dec 4, 2025 07:00 HKT/SGT
|
|
|
The 26th Hong Kong Forum marks successful completion
Dec 3, 2025 22:44: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
